文献速递免疫规划妇幼与学校卫生

一项3期、多中心、随机、双盲、阳性对照研究:评估15价肺炎球菌结合疫苗V114四剂方案在健康婴儿中的安全性、耐受性和免疫原性(PNEU-PED)

A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
PubMed 文献 · Vaccine · 2023-01-06

这项3期多中心随机双盲阳性对照研究纳入1720名健康婴儿,按1:1随机接受4剂V114或PCV13,并同时接种其他常规儿童疫苗。V114在全部15个血清型的IgG应答率上达到非劣效标准,在血清型3、22F和33F的IgG GMC上达到优效标准,安全性与PCV13总体相当。

要点

  • V114在全部15个血清型基于PD3 IgG应答率均达到非劣效标准。
  • V114对共享血清型3及独有血清型22F、33F在PD3和PD4的IgG GMC达到优效标准。
  • V114与PCV13在注射部位、全身和严重不良事件的比例、最大强度和持续时间上总体相当。

核心结论

  • 在健康婴儿中,V114显示出可接受的安全性和耐受性,并产生与PCV13相当的免疫应答。
  • V114对血清型3、22F和33F达到优效标准,结果支持将V114作为常规婴儿免疫规划的一部分用于预防肺炎球菌疾病。

研究设计与样本

  • 3期、多中心、随机、双盲、阳性对照研究,1720名健康婴儿按1:1随机接受4剂V114或PCV13,并同时接种其他常规儿童疫苗。
  • 安全性在每剂后以发生不良事件(AE)的受试者比例评估;血清型特异性抗肺炎球菌免疫球蛋白G(IgG)在PD3后1个月、第4剂前和PD4后1个月检测。
  • 比较两组的IgG应答率、几何平均浓度(GMC)和调理吞噬活性(OPA)。

主要发现

  • 注射部位、全身和严重不良事件的比例、最大强度和持续时间在V114组与PCV13组间总体相当。
  • 与PCV13相比,V114基于PD3 IgG应答率在全部15个血清型达到非劣效标准。
  • V114基于IgG GMC在PD3和PD4对除PD3血清型6A外的所有血清型达到非劣效标准。
  • V114诱导的抗体经OPA评估具有杀菌活性。
  • 与PCV13相比,V114在PD3和PD4基于血清型特异性IgG GMC对共享血清型3及独有血清型22F、33F达到优效标准。

关键数值与推荐

  • V114基于PD3 IgG应答率在全部15个血清型达到非劣效标准。
  • V114基于IgG GMC在PD3和PD4对除PD3血清型6A外的所有血清型达到非劣效标准。
  • V114在PD3和PD4基于血清型特异性IgG GMC对血清型3、22F、33F达到优效标准。

临床怎么用

  • 原文结论认为结果支持将V114作为常规婴儿免疫规划的一部分用于预防肺炎球菌疾病。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines (PCVs) confer protection against PD caused by most vaccine serotypes, but non-vaccine serotypes contribute to residual disease. V114 is a 15-valent PCV containing all 13 serotypes in Prevnar 13™ (PCV13) and additional serotypes 22F and 33F. This pivotal phase 3 study compared safety and immunogenicity of V114 and PCV13. METHODS: 1720 healthy infants were randomized 1:1 to receive a 4-dose regimen of V114 or PCV13 concomitantly with other routine pediatric vaccines. Safety was evaluated after each dose as proportion of participants with adverse events (AEs). Serotype-specific anti-pneumococcal immunoglobulin G (IgG) was measured at 1-month post-dose 3 (PD3), pre-dose 4, and 1-month post-dose 4 (PD4). IgG response rates, geometric mean concentrations (GMCs), and opsonophagocytic activity (OPA) were compared between vaccination groups. RESULTS: The proportion, maximum intensity, and duration of injection-site, systemic, and serious AEs were generally comparable between V114 and PCV13 groups. In comparison to PCV13, V114 met non-inferiority criteria for all 15 serotypes based on IgG response rates at PD3. V114 met non-inferiority criteria by IgG GMCs for all serotypes at PD3 and PD4, except for serotype 6A at PD3. V114-induced antibodies had bactericidal activity as assessed by OPA. Further, V114 met superiority criteria for shared serotype 3 and unique serotypes 22F and 33F compared to PCV13 by serotype-specific IgG GMCs at both PD3 and PD4. Immunogenicity of concomitantly administered routine pediatric vaccines was comparable in V114 and PCV13 groups. CONCLUSIONS: In healthy infants, V114 displays acceptable safety and tolerability profiles and generates comparable immune responses to PCV13. V114 also met superiority criteria for serotypes 3, 22F, and 33F. These results support use of V114 for prevention of PD as part of routine infant vaccination schedules. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03893448; EudraCT: 2018-004109-21.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lupinacci R, Rupp R, Wittawatmongkol O, et al. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine. 2023. PMID: 36621410. doi:10.1016/j.vaccine.2022.12.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。